Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a type of human coronavirus that resulted in the 2019 coronavirus disease (COVID-19). Although it was generally categorized as a respiratory disease, its involvement in cardiovascular complications was identified from the onset. Elevated cardiac troponin levels (a myocardial injury marker) and echocardiograms, which showed the anomalous performance of the patients’ hearts, were noted in the early case reports obtained from Wuhan, China. A couple of mechanisms have been proposed to explain COVID-19-induced cardiovascular complications, with systemic inflammation being the major focus recently. Chest pain and palpitations are among the prevalent symptoms in moderate to severe COVID-19-recovering patients. Cardiac damage potentially occurs due to multifactorial factors, which include cytokine-induced inflammation, direct cardiotoxicity, and disseminated intravascular coagulation (DIC), among others. The cardiovascular manifestations include cardiac arrhythmia, cardiogenic shock, venous thromboembolism, and elevated cardiac biomarkers. Both the long- and short-term effects of these cardiovascular complications remain puzzling to researchers, as substantial evidence is yet to be gathered to reach a consensus on the severity of COVID-19 in the heart. The treatment considerations currently include antiarrhythmic management, ACEI or ARB use, anticoagulation, hemodynamic support, and immunosuppression. This review aimed to outline the pathogenesis of the various cardiac complications due to COVID-19 as well as the available treatment modalities of COVID-19 infection. Both the mechanisms and the treatments have been succinctly explained in a proper manner to ensure understanding.

No abstract

This case report presents a case of a 51-year-old male patient who was found to be diabetic after recovering from COVID-19. Case Presentation: The patient was admitted to the COVID care center after testing positive for COVID-19 on November 2020. After spending one week in intensive care and ten days in the isolation ward of the COVID care center, he continued to feel multiple side effects. After fifteen days, he began showing signs of recovery and had no fever or other symptoms of COVID-19. The third SARS-Cov-2 RNA by RT-PCR sample test was also found to be negative. He was shifted to a non-COVID hospital when he became stable. For COVID-19, he was treated with supplementary oxygen therapy by keeping his oxygen level at 5L/min with titrating flow rate SpO2 of more than 90%. The hydroxychloroquine 400 mg orally BD for two days, followed by 200 mg orally BD for four days with a combination of azithromycin 500mg orally OD for five days, was prescribed to him to treat COVID-19. Conclusion: According to the report "New-onset diabetes in COVID-19," published in the New England Journal of Medicine, there is a bidirectional relationship between COVID-19 and diabetes.